Courtney Flaherty

Get the inside scoop from Drs Lou, Patel, and Beg on the top takeaways to come out of the 2025 Gastrointestinal Cancers Symposium.

The JAK/ROCK inhibitor rovadicitinib may provide a safe and effective new treatment option for patients with myelofibrosis who progressed on ruxolitinib.

The EMA’s CHMP has issued a positive opinion supporting the approval of subcutaneous amivantamab in EGFR-mutated NSCLC.

Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.

OS outcomes with lenvatinib plus pembrolizumab were prolonged in patients with PPP2R1A-mutated vs wild-type high-risk endometrial cancer.

Pooja Phull, MD, discusses real-world responses and survival outcomes with cilta-cel vs ide-cel in patients with relapsed/refractory multiple myeloma.

Inavolisib plus palbociclib/fulvestrant improved OS vs palbociclib/fulvestrant alone in PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.

Treatment with daraxonrasib at the phase 3 dose of 300 mg was well tolerated, had favorable dose intensity, and showed efficacy in RAS–mutated PDAC.

OS benefits with tislelizumab plus chemotherapy were comparable between early and late responders in the phase 3 RATIONALE-306 study in patients with ESCC.

An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.

The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.

Durable responses with UGN-102 signal its viability as a nonsurgical alternative to TURBT in low-grade, intermediate-risk NMIBC.

The FDA granted priority review to the BLA for RP1 plus nivolumab in advanced melanoma following progression on an anti–PD-1 agent.

The Fortel PSA Screening Test has been approved by the United Arab Emirates MOHAP for the rapid detection of early signs of prostate cancer.

Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.

Senaparib has received marketing authorization in China as a first-line maintenance therapy for advanced ovarian cancer.

David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.

Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.

The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.

Yousef Zakharia, MD, spotlights findings from 3 key trials informing the use of standard IO/TKI regimens in metastatic clear cell renal cell carcinoma.

Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.

Savolitinib has received full NMPA approval for locally advanced/metastatic non–small cell lung cancer with MET exon 14 skipping alterations.

Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.

Erica L. Mayer, MD, MPH, responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative breast cancer.

Daniel DeAngelo, MD, PhD, discusses the expanded role of blinatumomab in B-cell precursor acute lymphoblastic leukemia management

The phase 3 ALA-BCC-CT013 study of Ameluz and RhodoLED PDT in sBCC had its last enrolled patient complete a 1-year follow-up visit.

Enfortumab vedotin-efjv plus has received NMPA approval for patients with locally advanced or metastatic urothelial cancer.

Flonoltinib maleate generated rapid clinical benefits, including spleen volume reduction and symptom improvement, for patients with myelofibrosis.

Tom van Meerten, MD, PhD, discusses key efficacy and safety data with brexu-cel in BTK inhibitor–naive relapsed/refractory mantle cell lymphoma.

Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.